MGMichelle Gill

Michelle Gill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michelle Gill has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Comparison of Five Simplified Scales to the Out‐of‐hospital Glasgow Coma Scale for the Prediction of Traumatic Brain Injury Outcomes

    by Michelle Gill, Robert Steele, Ryan Windemuth, Steven M. Green

    Background: The 15‐point Glasgow Coma Scale (GCS) frequently is used in the initial evaluation of traumatic brain injury (TBI) in out‐of‐hospital settings. We hypothesized that the GCS might be unnecessarily complex for out‐of‐hospital use. Objectives: To assess whether a simpler scoring system might demonstrate similar accuracy in the prediction of TBI outcomes. Methods: We performed a retrospective analysis of a trauma registry consisting of patients evaluated at our Level 1 trauma center from 1990 to 2002. The ability of out‐of‐hospital GCS scores to predict four clinically relevant TBI outcomes (emergency intubation, neurosurgical intervention, brain injury, and mortality) by using areas under receiver operating characteristic curves (AUROCs) was calculated. The same analyses for five simplified scales were performed, and compared with the predictive accuracies of the total GCS score. Results: In this evaluation of 7,233 trauma patients over a 12‐year period of time, the AUROCs for the total GCS score were 0.83 (95% confidence interval [CI] = 0.81 to 0.84) for emergency intubation, 0.86 (95% CI = 0.85 to 0.88) for neurosurgical intervention, 0.83 (95% CI = 0.82 to 0.84) for brain injury, and 0.89 (95% CI = 0.88 to 0.90) for mortality. The five simplified scales approached the performance of the total GCS score for all clinical outcomes. Conclusions: In the evaluation of injured patients, five simplified neurological scales approached the performance of the total GCS score for the prediction of four clinically relevant TBI outcomes.


  • Cognitive Performance Following Modafinil versus Placebo in Sleep‐deprived Emergency Physicians: A Double‐blind Randomized Crossover Study

    by Michelle Gill, Paul Haerich, Kelli Westcott, Kristen L. Godenick, Jennifer A. Tucker

    Objectives: Modafinil has recently been approved for the treatment of shift work sleep disorder, making it potentially available for shift‐working emergency physicians. The authors' objectives were to determine whether modafinil improved cognitive performance of emergency physicians following overnight shifts and to record symptoms and subjective evaluations of the effect of modafinil on the participants. Methods: This was a randomized, double‐blind, placebo‐controlled crossover study that followed CONSORT guidelines. Participants were assigned to one of two study groups, with study sessions occurring at least seven weeks apart, and received either modafinil or placebo depending on their random allocation. Testing after night shifts included a coding task and an AX version of the Continuous Performance Task, both of which test cognitive function. Participants also completed visual analog scales for three subjective outcomes, and symptoms were elicited. Results: Modafinil facilitated performance on long interstimulus‐interval AX trials (F [1, 23] = 6.65, p = 0.1) and marginally reduced errors on AY trials in the Continuous Performance Task (F [1, 23] = 3.59, p = 0.07), suggesting facilitation of sustained attention, cognitive control, and working memory. Additionally, modafinil, compared with placebo, facilitated performance on the coding task at the first session. Subjective data from visual analog scales confirmed that modafinil increased perceived alertness during the simulated patient care sessions but worsened sleep onset when opportunities for sleep arose. Conclusions: Modafinil increased certain aspects of cognitive function and subjectively improved participants' ability to attend post–night‐shift didactic sessions but made it more difficult for participants to fall asleep when opportunities for sleep arose.


  • Validation Study of Fractional Exhaled Nitric Oxide Measurements Using a Handheld Monitoring Device

    by Michelle Gill, Gavin R. Graff, Alan J. Adler, Raed A. Dweik

    We tested reproducibility of exhaled nitric oxide (FE(NO)) and inter-operator handling when measured with a handheld device, NIOX MINO. We enrolled 20 volunteers using a priori goals of acceptable reproducibility to be mean within-subject standard deviation less than 3 parts per billion (ppb) for FE(NO) measurements less than 30 ppb, and mean coefficient of variation less than 10% for FE(NO) measurements more than 30 ppb. Seventeen subjects with measurements less than 30 ppb displayed a mean standard deviation of 1.15, and 3 subjects with FE(NO) more than 30 ppb had a mean coefficient of variation of 2.4%. We conclude that NIOX MINO demonstrates excellent reproducibility for all ranges of FE(NO).


  • Exhaled Nitric Oxide Levels during Acute Asthma Exacerbation

    by Michelle Gill, Scott Walker, Aqeel Khan, Steven M Green, Lillian Kim, Shaun Gray, Baruch Krauss

    Fractional exhaled nitric oxide (FE(NO)) has been shown in laboratory settings and trials of patients with stable asthma to correlate with the degree of airway inflammation. The authors hypothesized that the technique of measuring FE(NO) would be reproducible in the setting of acute asthma in the emergency department (ED) and that the FE(NO) results during ED visits would potentially predict disposition, predict relapse following discharge, and correlate with the National Institutes of Health (NIH) asthma severity scale and peak expiratory flow measurements. The authors prospectively measured FE(NO) in a convenience sample of ED patients with acute exacerbations of asthma, both at the earliest possible opportunity and then one hour later. Each assessment point included triplicate measurements to assess reproducibility. The authors also performed spirometry and classified asthma severity using the NIH asthma severity scale. Discharged patients were contacted in 72 hours to determine whether their asthma had relapsed. The authors discontinued the trial (n = 53) after a planned interim analysis demonstrated reproducibility (coefficient of variation, 15%) substantially worse than our a priori threshold for precision (4%). There was no association between FE(NO) response and corresponding changes in spirometry or clinical scores. Areas under the receiver operating characteristic curves for the prediction of hospitalization and relapse were poor (0.579 and 0.713, respectively). FE(NO) measurements in ED patients with acute asthma exacerbations were poorly reproducible and did not correlate with standard measures of asthma severity. These results suggest that using existing technology, FE(NO) is not a useful marker for assessing severity, response to treatment, or disposition of acute asthmatic patients in the ED.